---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-005802"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T16:39:21.716341+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics posts Q4 net income $23.3M; FY 2024 BRIUMVI revenue $310M, guides 2025 global rev ~$540M

## Summary
- Q4 2024 BRIUMVI U.S. net revenue $103.6M; full year $310M, representing ~250% YoY growth.
- Net income of $23.3M in Q4 2024 vs net loss of $14.4M in Q4 2023; full year net income $23.4M.
- 2025 guidance: total global revenue ~$540M, including BRIUMVI U.S. net revenue ~$525M; operating expenses ~$300M.
- Cash, cash equivalents and investments $311M as of Dec 31, 2024; company expects sufficient funding from revenues.
- Pipeline: Phase 1 trials for subcutaneous ublituximab in MS and MG; licensed azer-cel CAR T for autoimmune indications.

## SEC filing metadata
- accession: 0001437749-25-005802
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000143774925005802/0001437749-25-005802-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000143774925005802/tgtx20250225_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-005802
- JSON: https://secwatch.observer/filing/0001437749-25-005802.json
- Plain text: https://secwatch.observer/filing/0001437749-25-005802.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.